A Study to Evaluate Subcutaneous Durvalumab in Patients with Non-Small Cell Lung Cancer and Small Cell Lung Cancer - SCope-D1

Study identifier:D9072C00001

ClinicalTrials.gov identifier:NCT04870112

EudraCT identifier:2020-006041-18

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase 1/2a, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients with Non-Small Cell and Small Cell Lung Cancer – SCope-D1

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

Durvalumab, Cisplatin, Carboplatin, Etoposide

Sex

All

Actual Enrollment

18

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 28 Jun 2021
Primary Completion Date: 30 Aug 2023
Study Completion Date: 30 Aug 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria